Current location: Home > News > Company news
Arctic Vision Triumphs at the 16th APVRS Congress!

The recently concluded 16th annual Asia-Pacific Vitreo-retina Society (APVRS) Congress, held in Hong Kong from December 8-10, marked a significant achievement for Arctic Vision.


As a key gathering for experts in Ophthalmology worldwide, APVRS attracted over 2,100 delegates from 42 countries, providing an ideal platform for Arctic Vision to engage with global leaders in ophthalmology and stay abreast of cutting-edge technology.


Our revolutionary dry eye neurostimulation device, iTEAR®, the first and only FDA-cleared non-invasive technology to relieve dry eyes, captivated attendees with its drug-free approach, easy-to-use design, and revolutionary mechanism to stimulate lacrimal glands, meibomian glands, and goblet cells simultaneously for natural tears. After a successful year in the Hong Kong market, iTEAR® continues to earn acclaim from patients and physicians. Meanwhile, we also presented our innovative strength as a unicorn in the ophthalmic market, and comprehensive product ecosystem for the needs of patients and consumers throughout their full-age life cycle in our exhibition.



On-site product consultation and trial at Arctic Vision booth

Beyond that, collaborating with Dr. Raymond Wong, an esteemed ophthalmologist at C-MER Eye Centre and APVRS council member, we presented a poster on the ARVN001 PEACHTREE post-hoc analysis, titled "Clinical Outcomes in Managing Macular Edema in Patients with Non-infectious Uveitis Treated with Suprachoroidal Injections of Triamcinolone Acetonide Suspension: A Post-hoc Analysis of a Phase III Study." The poster earned Dr. Wong the Best Poster Award, a proud moment for the entire Arctic Vision team!


Arctic Vision and Dr. Raymond WONG's contribution was awarded Best Poster Awar

This post-hoc analysis of the Phase III clinical trial aimed to evaluate whether baseline disease characteristics impact the efficacy of suprachoroidal injections of triamcinolone acetonide in treating macular edema associated with non-infectious uveitis. Results demonstrated significant improvements from baseline in BCVA and CST in all groups at all visits, with trends that earlier diagnosis and shorter disease duration may lead to better improvements, suggesting earlier treatment upon diagnosis.


Group photo of Arctic Vision Hong Kong team at the APVRS booth

Attending APVRS in person after the pandemic was a fantastic opportunity for the Arctic Vision team. We're thrilled with the successful results and look forward to reuniting next year for more innovative discussions.

For the full abstract, visit:

About Arctic Vision

Arctic Vision is a China-based ophthalmic biotech focusing on breakthrough therapies, with a leading portfolio covering pre-clinical stage to commercial stage products. Our vision is to provide innovative therapies in China, Asia and globally to address unmet clinical needs and benefit ophthalmic patients at large. Arctic Vision is supported by top-tier life sciences investors and led by an elite team of ophthalmic industry veterans with substantial regional and global experiences in R&D and commercialization of ophthalmic products. 

For investor and media enquiries, please contact

@1Suite 906-908, 9F, Tower II, Century Link, 1196 Century Avenue, Shanghai, China @2Suite A09, 10th Floor, Twin Towers (East), B 12 Jianguomenwai Avenue, Beijing, China @3Suite 2305, 23/F, The Gateway Prudential Tower, Harbour City, No 21 Canton Road, Tsim Sha Tsui, Kowloon, Hong Kong @4Suite Level 5 63 Pirie Street, Adelaide, SA 5000, Australia

To report a potential adverse event, please refer to the contact information below:


Mainland China:

Hong Kong, China: